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Abstract
This chapter reviews the current literature in view of varying clinical practices surround-
ing the diagnostic role of renal tumor biopsies of small renal masses. Surgical manage-
ment of small renal masses without pretreatment biopsy is a routine strategy in many 
urological centres around the world. This is in spite of improvements in techniques, 
accuracies and biomarkers to diagnose the neoplasm. Apart from its effectiveness, renal 
tumor biopsies avoid the risks of surgically treating benign renal masses and may also 
prove cost-effective to healthcare systems. Interdisciplinary communication between 
urologists, interventional radiologists and pathologists will facilitate the process of mak-
ing this biopsy-driven management the standard of care.
Keywords: active surveillance, biopsy, diagnostic accuracy, intratumour heterogeneity, 
kidney neoplasms, renal cell carcinoma, renal tumor biopsy, partial nephrectomies, 
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1. Introduction
The surgical disposition towards partial nephrectomies and ablative techniques in the man-
agement of small renal masses (SRMs) urges the use of biopsies to overcome preoperative 
misclassifications.
SRMs are defined to be T1a tumors ≤4 cm in greatest dimension, limited to the kidneys. 
With improved medical imaging, the incidence of patients with SRMs has been rising. 
These patients tend to be asymptomatic and show a good prognosis. The current European 
Association of Urology (EAU) guidelines promote nephron-sparing techniques, especially 
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partial nephrectomies (PN) in the management of T1a tumors. Other approaches such as 
radiofrequency ablation (RFA), cryotherapy and active surveillance (AS) are also considered.
However, it has been shown that a large proportion of SRMs treated are benign incidentalomas. 
Twenty percent of surgically removed SRMs have proven to be benign [1, 2] (angiomyolipoma, 
oncocytoma, metanephric adenoma, etc.), with the figure rising to 29% for tumors <2.5 cm [3]. 
Thus, it is necessary for current practices to be reevaluated to avoid unnecessary overtreatment.
Surgical management based on CT imaging, without pretreatment biopsy, is considered 
appropriate in most centres. Such an approach not only leads to the patient undertaking 
unnecessary surgical risks but also places a significant burden on the healthcare system. 
Premanagement renal tumour biopsies (RTBs) have the potential to not only offer holistic 
approach to their management but can equally be cost-effective.
Opponents to RTBs believe that concordance rates of the final pathology with radiologi-
cal imaging, false-negative rates and potential seeding make this an unreliable procedure. 
However, the safety and outcomes of RTBs have improved significantly over the last decade. 
Improved imaging techniques allow for a specific localized tissue to be biopsied. Samples 
taken from percutaneous needle biopsies also now utilize biomarkers that can lend further 
insights to the heterogeneous nature of renal neoplasms.
It is important to recognize that avoiding unnecessary surgical treatments is more cost-effec-
tive and negates associated risks. In this chapter, we will discuss the improvements of RTBs 
and the merits of incorporating them to deliver better outcome measures.
2. Protocol of SRM management
It is estimated that 60% of all diagnosed renal cell carcinomas (RCCs) are SRMs that are dis-
covered as incidentalomas on ultrasound and/or abdominal CT scans [4]. The current protocol 
in many urological renal centres, following the discovery of a SRM, is to offer the patient treat-
ment options without a biopsy. Generally, unless contraindicated, these options include PN, 
RFA, or AS. This approach to treating a SRM is done without a clear histological diagnosis.
There should be a paradigm shift on how SRMs are approached. In some centres, RTBs are 
now performed upon the discovery of an incidentaloma. Here, patients are referred to an 
interventional radiologist who will then perform a RTB before their consultation with their 
urologist. Following the biopsy results from the pathologist, the urologist will meet the 
patient and offer better informed treatment options.
3. Contemporary indications and contraindications for biopsy
The EAU guidelines recommend RTBs to be performed for AS on selected patients with 
SRMs, prior to ablative treatments and patients suffering from renal metastatic disease before 
embarking on systemic treatment.
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The American Urological Association (AUA) guidelines stipulate that biopsies should be 
considered when a renal mass is suspected to be metastatic, hematological, inflammatory or 
infectious. RTBs are also expected to be performed before ablative procedures.
Historically, absolute contraindications to RTBs include uncontrolled severe hypertension, 
inability to cooperate with biopsy, solitary kidney and uncontrollable bleeding diathesis [5]. 
Relative contraindications may include a lack of a safe pathway to the lesion and pregnancy 
where imaging guidance involves ionizing radiation.
4. Prevalence of biopsies
Recent studies have shown that RTBs are still not widely adopted among urologists in clinical 
practice. A survey in 2010 by Barwari et al. [6] showed that 73% of urologists never take biop-
sies and only 9% take biopsies in more than 25% of cases. Another survey in 2016 by Richard 
et al. [7], investigating the prevalence of biopsies for SRMs, showed that only 12% perform 
RTBs in >75% of cases, while 53% never perform or perform RTBs in <25% of cases.
In both surveys the main reasons urologists cited for not performing biopsies were the lack of 
influence in clinical management, the risk of false negatives and safety. There is also a radiol-
ogy-related concern of a lack of expertise with RTBs [7]. These concerns will have to be tackled.
4.1. Prevalence of RTBs in active surveillance
In current literature, many patients undergoing AS have not had a biopsy [8–10]. AS is usu-
ally indicated for elderly patients with significant comorbidities or those refusing surgery. 
Though considered a safe option for patients with SRMs, the risk of developing metastatic 
disease during surveillance is not ruled out. A systematic review performed by Prins et al. 
[9] showed that though 1.12% (0–3.2%) of the pooled AS population (968 patients) incurred 
delayed intervention, only a small proportion of the said population had undergone a RTB. If 
a biopsy had been performed, it could have led to an earlier appropriate intervention [11]. A 
systematic review performed by Smaldone et al. [10] looked at the incidence of metastases 
in AS strategies. In this review of 880 patients, 18 patients (2.05%) progressed to metastatic 
disease. Unfortunately, only three of these patients had undergone a RTB.
RTBs can also pave the way for a more refined AS strategy and are strongly recommended 
[8, 10, 12, 13]. If the SRM proves to be histologically benign, a less stringent follow-up pro-
tocol can be adopted, or the patient may even be discharged. Higher metastatic potential 
masses that are better suited for surgical intervention can also be identified. Thus, RTBs 
can stratify patients into a low-risk or high-risk surveillance strategy.
4.2. Prevalence of RTBs in radiofrequency ablation
In some centres performing RFA, RTBs are either done at the time of the procedure or not 
performed at all [14–16]. These patients continue to be treated with a presumptive diagnosis 
of renal cancer based on CT/US imaging. This increases the rate of RFA performed for benign 
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or indeterminate pathology [15]. Performing RTBs prior to ablative techniques can also be 
used to stratify patients—where those with unfavorable histology can be triaged to surgery 
instead.
5. Addressing barriers
In order to facilitate the shift in managing SRMs (be it in AS, RFA or systemic treatment), it is 
important for us to address these barriers in adopting RTBs. We will now assess the reliability 
and improvements of RTBs.
5.1. Improved techniques for biopsy
RTBs are performed percutaneously under local anesthesia. It can be with needle core biopsy 
or fine needle aspiration (FNA) with US or CT guidance.
Core needle biopsies yield a higher diagnostic rate and a more accurate histological examina-
tion over FNA. This was exemplified by a systematic review performed by Marconi et al. 
[17] (57 studies recruiting 5228 patients)—showing superior sensitivities and specificities over 
diagnostic FNAs. A coaxial technique allows multiple biopsies to be taken through a coaxial 
canula, avoiding potential tumor seeding. Comparing needle sizes used, 18-gauge needles 
are preferred over 14- and 20-gauge needles—showing safer and more accurate histological 
results [18, 19].
With regard to imaging modalities, US and CT possess their own merits. CT has the advantage 
of a better resolution that is ideal to locate lesions that are in proximity to critical structures. 
US has the advantage of lower radiation and lower cost. More importantly it allows real-time 
needle placement that is suited for nonfocal renal lesions [20].
In spite of acknowledging preferred techniques of RTBs, there are other technical factors 
that affect their success: amount of adipose tissue in the patient, echogenicity and location of 
lesion. The challenge of performing a successful biopsy can thus vary from lesion to lesion. 
Effective communication between the interventional radiologist and urologist is necessary to 
ensure that a RTB would be reliable in managing a specific SRM.
5.2. Improvements in accuracy
Recent literature lends support to the diagnostic accuracies of RTBs, challenging the notions 
some urologists believe. The meta-analysis performed by Marconi et al. [17] showed that ini-
tial RTBs yielded a diagnosis in >90% of cases. Core biopsies showed a high sensitivity and 
specificity of 99.1 and 99.7%, respectively. In cases where both a RTB and surgical pathol-
ogy were available, good concordance (k = 0.683) for tumor histotype and fair concordance 
(k = 0.34) for tumor grade were shown.
A systematic review by Patel et al. [21] (including 20 studies with 2979 patients) showed a 
high diagnostic accuracy of RTB with a sensitivity of 97.5% and a specificity of 96.2%. There 
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was also a high histological concordance observed. Patel’s study highlighted the concern of a 
reasonable non-diagnostic rate (14.1%).
However, repeat biopsy led to diagnosis in 80% of previously undiagnostic biopsies. It is 
reported that following a non-diagnostic biopsy, a repeat biopsy has a high rate of rendering 
a diagnosis—ranging from 67 to 85% [22]. Therefore, in the case of a non-diagnostic biopsy, 
there is merit in performing a repeat biopsy.
With overall improved diagnostic accuracies of RTBs, urologists should be more reassured 
about their successes.
5.3. Managing complications
Reported concerns regarding the safety of RTBs stem from the risks of bleeding, pneumotho-
rax and tumor seeding [7]. Rising literature appraising the choice of gauge needles, imaging 
modality and preference for core biopsies over FNA have improved the safety of RTBs.
In Patel’s et al. study [21], complication rates observed were quite low. The rate of haemato-
mas was 4.9%, while the occurrence of any clinically significant pain was 1.2%. Pneumothorax 
was only detected in 0.6% of cases, and no study reported any cases of tumor seeding. In 
Marconi’s et al. study [17], the median complication rate was 8.1% with only three Clavien 
grade ≥2 complications to be reported.
Tumor seeding along the needle tract is anecdotal and very rare. As per the EAU reported 
guidelines, to avoid any such complication, coaxial sheaths should be used. This allows mul-
tiple passes through the renal mass with only one through surrounding tissue.
5.4. Discerning tumour heterogeneity
Despite the high concordance rates in identifying tumor subtypes (as mentioned above), the 
heterogeneous nature of RCC in itself is an identified barrier in adopting RTB. It is essential 
for clinicians to identify the challenges in discerning between specific tumor subtypes in order 
to have a comprehensive grasp on the reliability of a RTB.
The four main subtypes of RCC include clear cell RCC (ccRCC), papillary RCC (pRCC), 
chromophobe RCC (chRCC) and collecting duct carcinoma (CDC). There are over 10 such 
subtypes with many inherited syndromes [23]. Each subtype is associated with its own prog-
nostic factors from clinically indolent (pRCC type 1, chRCC) to highly metastatic (pRCC type 
2 or ccRCC). Thus, it is valuable for a subtype to be distinguished from benign lesions and also 
to be reliably identified for a more tailored management.
Another systematic review by Patel et al. [24] investigated the success of identifying oncocyto-
mas. Of the 48 lesions that were diagnostic of oncocytoma on RTB, 64.6% was in concordance 
with analysis following surgical treatment. Meta-analysis determined the PPV of oncocytoma 
on RTB to be 67% with a notable proportion to be identified as chRCC. Histologically, they 
are hard to distinguish as both have an eosinophilic cytoplasm. Clinical diagnostic dilemmas 
between chRCC and oncocytomas still remain. Clinicians should factor this in tailoring an 
altered AS for oncocytomas.
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6. Investigating biomarkers
Recent studies have explored the merits of molecular biomarkers to improve diagnostic clas-
sification of RTBs. A recent systematic evaluation by Gulati et al. [25] assessed cancer-specific 
survival (CSS) in 350 ccRCC patients with 28 published genetic biomarkers. Seventeen of 
these genetic and transcriptomic prognostic ccRCC markers were validated as predictors of 
CSS. A comprehensive review article by Farber et al. [26] shows the many other areas where 
biomarkers are being developed: PET imaging, MRI, serum biomarkers, urine biomarkers, 
liquid biopsy and immunohistochemistry. Of particular interest is the staining method for 
CK7 that is expressed in both chRCC and oncocytoma. In the former it is strongly and dif-
fusely positive, while in the latter, only focal positivity or no staining is observed [18, 26, 27]. 
With further prospective clinical studies, a combinatorial approach can be adopted to discern 
the heterogeneous nature of renal lesions.
7. Cost-effectiveness
It is critical to stress on the cost-effectiveness of integrating RTBs in the management of SRMs. 
A cost-effectiveness study by Pandharipande et al. [28] showed that a strategy of pretreatment 
biopsies of SRMs leads to a minimally greater difference of quality-adjusted life expectancy 
(4 days) than empiric surgery. This is at a lower lifetime cost of ($3466). Avoiding unneces-
sary surgery in cases of resecting indolent SRMs is in the interests of both the patient and the 
healthcare system. With similar outcomes and lower cost, the use of biopsy to triage patients 
facilitates this.
8. Conclusion
RTBs have the strong potential to avoid unnecessary surgeries, preventing treatment-related 
morbidities in patients and saving healthcare costs. RTBs have high diagnostic accuracies, 
high concordance rates and low complication rates. Therefore, RTBs should be integrated in 
the pretreatment management of SRMs when their results can alter the treatment options for 
the patient. Further studies in improving diagnostic biomarkers are worthwhile in supple-
menting the classification of RCC subtypes.
This shift in management away from empiric surgical treatment requires support from inter-
ventional radiologists, histopathologists and urologists. An interventional radiologist would 
be suited in identifying the preferred imaging modality for a specific RTB and explaining the 
difficulty to obtain an adequate amount for a reliable diagnosis. A histopathologist can raise 
concerns on potential misclassifications of specific tumor subtypes.
Integrated clinical communication between these disciplines can optimize the effective use of 
a RTB in crafting a well-suited treatment plan for the patient.
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